Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (6805)	6/24/1999 3:25:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9719

Please call NASDAQ and ask them to double the price (BTRN) tomorrow. V1..... haven't had time to answer your question re. reimbursement issues and Adcon-L. Long story. The assn. between scarring and Adcon was apparent. The assn. between pain and scarring was less apparent, and just plain unclear for Adcon and pain. However, they now have significant assn. between Adcon and pain for at least one measure. They also have a "monograph" manuscript that deals with the cost issues, quite favorably. I'll see if I can dig up an abstract. Labeling for pain, despite no direct assn., was quite good. Demand and penetration have been strong, so the issue will be coming up more frequently. From everything that I've seen, it's compelling to pay for the device-goo. There's potential approval in Japan, verdict expected this year. Solid progress, so I've heard (no direct info collection), toward reimbursement in France. Rick